retatrutide type 2 diabetes phase 2 results 2024 2025 π¨ Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. π Mean body weight change at 80 weeks: β¬οΈ Efficacy and Safety of GLPβ1
Pay in 4 interest-free payments of $6.55 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Aug 1 - Aug 6


























